U.S. investors and pharmaceutical giants are increasingly looking to China for drug innovation, with nearly 30% of major pharma deals last year involving Chinese companies—up from 0% in 2019.

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

We hoped industry layoffs would relent in ... Story Feb. 6 - X4 Pharmaceuticals: The rare disease biotech is laying off 43 employees—equivalent to 30% of the company’s total staffers—along ...

By fusing circular dichroism with high-resolution microspectroscopy and microscopic imaging, this cutting-edge technology is ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, ...

Some 4,000 biotech industry businesses employ about 40,000 workers at well-above-average wages, with ripple effects across ...